Leiomyosarcoma Clinical Trials in New York, NY

View the best 10 leiomyosarcoma medical studies in New York, New York. Access promising new therapies by applying to a New York-based Leiomyosarcoma clinical trial.

Trials in New York, New York

Here are the top 10 medical studies for leiomyosarcoma in New York, New York

Temozolomide +1 More

Alkylating agents

Recruiting1 awardPhase 2 & 3

This trial is comparing the effectiveness of a combination treatment using olaparib and temozolomide to the common chemotherapy drugs trabectedin or pazopanib. The trial is for patients

Surgery

Recruiting2 awardsPhase 3

This trialtests if chemo before surgery can help people with a certain type of cancer live longer.

Temozolomide +1 More

Alkylating agent

Recruiting1 awardPhase 2 & 3

This trial compares using a PARP inhibitor and alkylating agent to usual treatment for advanced uterine leiomyosarcoma after chemotherapy. The combo may be more effective.

Tabelecleucel

Virus Therapy

Recruiting1 awardPhase 2

This trial tests tabelecleucel, a treatment using special immune cells, in patients with certain diseases related to the Epstein-Barr virus (EBV) who can't use or don't respond to standard treatments. It works by enhancing the immune system's ability to attack virus-infected cells. Tabelecleucel is being tested for recurring or hard-to-treat EBV-related diseases.

Lurbinectedin +1 More

Chemotherapy

Recruiting1 awardPhase 1 & 2

This trial is testing a new drug, lurbinectedin, combined with an existing chemotherapy drug, doxorubicin, in patients with advanced leiomyosarcoma. The goal is to see if this combination is safe and more effective than doxorubicin alone. Both drugs work by damaging the DNA in cancer cells, leading to their death. Lurbinectedin is a synthetic marine-derived anticancer agent that has shown promise in treating certain types of cancer.

Radiation Therapy +1 More

Radiation

Recruiting1 awardPhase 2

This trial is studying the side effects of talimogene laherparepvec and radiation therapy in treating patients with newly diagnosed soft tissue sarcoma.

Ipilimumab, Nivolumab

Checkpoint Inhibitor

Recruiting1 awardPhase 2

This trial tests 2 combinations of drugs to fight advanced soft tissue sarcoma: immunotherapy and chemotherapy.

Doxorubicin

Anti-tumor antibiotic

Recruiting1 awardPhase 2

This trial is testing whether adding a new drug to standard treatment can help people with leiomyosarcoma that has spread to other parts of the body.

Doxorubicin +2 More

Anthracyclines

Recruiting1 awardPhase 2 & 3

This trial is testing whether a new drug called pazopanib, when combined with chemotherapy and radiation, works better for patients with a specific type of soft tissue cancer. Pazopanib helps stop cancer cells from growing, while chemotherapy and radiation kill the cells. The goal is to see if this combination can improve treatment outcomes.

Letrozole

Aromatase Inhibitor

Recruiting1 awardPhase 2

This trial is testing a drug called letrozole in patients with a type of cancer called uterine leiomyosarcoma. The goal is to see if letrozole can help patients live

Popular Filters

Trials With No Placebo

Checkpoint Inhibitor

Immunotherapy + Chemotherapy for Soft Tissue Sarcoma

Recruiting1 awardPhase 2

New York, New York

This trial tests 2 combinations of drugs to fight advanced soft tissue sarcoma: immunotherapy and chemotherapy.

Aromatase Inhibitor

Letrozole for Leiomyosarcoma

Recruiting1 awardPhase 2

Willow Grove, Pennsylvania

This trial is testing a drug called letrozole in patients with a type of cancer called uterine leiomyosarcoma. The goal is to see if letrozole can help patients live

Alkylating agent

Olaparib + Temozolomide for Uterine Leiomyosarcoma

Recruiting1 awardPhase 2 & 3

New York, New York

This trial compares using a PARP inhibitor and alkylating agent to usual treatment for advanced uterine leiomyosarcoma after chemotherapy. The combo may be more effective.

Alkylating agents

Olaparib + Temozolomide for Uterine Leiomyosarcoma

Recruiting1 awardPhase 2 & 3

Montvale, New Jersey

This trial is comparing the effectiveness of a combination treatment using olaparib and temozolomide to the common chemotherapy drugs trabectedin or pazopanib. The trial is for patients

Chemotherapy

Lurbinectedin + Doxorubicin for Leiomyosarcoma

Recruiting1 awardPhase 1 & 2

New York, New York

This trial is testing a new drug, lurbinectedin, combined with an existing chemotherapy drug, doxorubicin, in patients with advanced leiomyosarcoma. The goal is to see if this combination is safe and more effective than doxorubicin alone. Both drugs work by damaging the DNA in cancer cells, leading to their death. Lurbinectedin is a synthetic marine-derived anticancer agent that has shown promise in treating certain types of cancer.

Checkpoint Inhibitor

Rucaparib + Nivolumab for Leiomyosarcoma

Recruiting2 awardsPhase 2

Montvale, New Jersey

This trial is testing whether combining two drugs, rucaparib and nivolumab, may be effective in treating leiomyosarcoma (LMS), a type of cancer.

Frequently Asked Questions

Do I need insurance to participate in a trial?

Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).

Is there any support for travel costs?

Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.

Will I know what medication I am taking?

This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.

How long do clinical trials last?

Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.

Do you verify all the trials on your website?

All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.

How quickly will I hear back from a clinical trial?

Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.